Evidence map›Paper›PMID 38750529›Full record

ArticleAIDS research and therapy2024

Rapid antiretroviral therapy initiation following rollout of point-of-care early infant diagnosis testing, Uganda, 2018-2021.

Stella M Migamba, Tamara Nsubuga Nyombi, Edirisa Juniour Nsubuga, Andrew Kwiringira, Augustina Delaney, Steven Ndugwa Kabwama, Mary Nakafeero, Benon Kwesiga, Daniel Kadobera, Phoebe Monalisa-Mayambala and 3 more

Abstract read
In one paragraph

Article in AIDS research and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Stella M MigambaUganda Public Health Fellowship Program, Uganda National Institute of Public Health, Kampala, Uganda. smigamba@musph.ac.ug.
Tamara Nsubuga NyombiDivision of Global HIV and Tuberculosis, U.S. Centers for Disease Control and Prevention, Kampala, Uganda.
Edirisa Juniour NsubugaUganda Public Health Fellowship Program, Uganda National Institute of Public Health, Kampala, Uganda.
Andrew KwiringiraUganda Public Health Fellowship Program, Uganda National Institute of Public Health, Kampala, Uganda.
Augustina DelaneyDivision of Global HIV and Tuberculosis, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia.
Steven Ndugwa KabwamaUganda Public Health Fellowship Program, Uganda National Institute of Public Health, Kampala, Uganda.
Mary NakafeeroMakerere University School of Public Health, Kampala, Uganda.
Benon KwesigaUganda Public Health Fellowship Program, Uganda National Institute of Public Health, Kampala, Uganda.
Daniel KadoberaUganda Public Health Fellowship Program, Uganda National Institute of Public Health, Kampala, Uganda.
Phoebe Monalisa-MayambalaDivision of Global HIV and Tuberculosis, U.S. Centers for Disease Control and Prevention, Kampala, Uganda.
Lilian BulageUganda Public Health Fellowship Program, Uganda National Institute of Public Health, Kampala, Uganda.
Alex Riolexus ArioUganda Public Health Fellowship Program, Uganda National Institute of Public Health, Kampala, Uganda.
Julie R HarrisDivision of Global Health Protection, U.S. Centers for Disease Control and Prevention, Kampala, Uganda.

Funding

President's Emergency Plan for AIDS Relief (PEPFAR) through US Centre for Disease Control and Prevention GH001353-01
6 · The paper itself

Abstract

backgroundUganda Ministry of Health (MOH) recommends a first HIV DNA-PCR test at 4-6 weeks for early infant diagnosis (EID) of HIV-exposed infants (HEI) and immediate return of results. WHO recommends initiating antiretroviral therapy (ART) ≤ 7 days from HIV diagnosis. In 2019, MOH introduced point-of-care (POC) whole-blood EID testing in 33 health facilities and scaled up to 130 facilities in 2020. We assessed results turnaround time and ART linkage pre-POC and during POC testing.

methodsWe evaluated EID register data for HEI at 10 health facilities with POC and EID testing volume of ≥ 12 infants/month from 2018 to 2021. We abstracted data for 12 months before and after POC testing rollout and compared time to sample collection, results receipt, and ART initiation between periods using medians, Wilcoxon, and log-rank tests.

resultsData for 4.004 HEI were abstracted, of which 1.685 (42%) were from the pre-POC period and 2.319 (58%) were from the period during POC; 3.773 (94%) had a first EID test (pre-POC: 1.649 [44%]; during POC: 2.124 [56%]). Median age at sample collection was 44 (IQR 38-51) days pre-POC and 42 (IQR 33-50) days during POC (p < 0.001). Among 3.773 HEI tested, 3.678 (97%) had test results. HIV-positive infants' (n = 69) median age at sample collection was 94 (IQR 43-124) days pre-POC and 125 (IQR 74-206) days during POC (p = 0.04). HIV positivity rate was 1.6% (27/1.617) pre-POC and 2.0% (42/2.061) during POC (p = 0.43). For all infants, median days from sample collection to results receipt by infants' caregivers was 28 (IQR 14-52) pre-POC and 1 (IQR 0-25) during POC (p < 0.001); among HIV-positive infants, median days were 23 (IQR 7-30) pre-POC and 0 (0-3) during POC (p < 0.001). Pre-POC, 4% (1/23) HIV-positive infants started ART on the sample collection day compared to 33% (12/37) during POC (p < 0.001); ART linkage ≤ 7 days from HIV diagnosis was 74% (17/23) pre-POC and 95% (35/37) during POC (p < 0.001).

conclusionPOC testing improved EID results turnaround time and ART initiation for HIV-positive infants. While POC testing expansion could further improve ART linkage and loss to follow-up, there is need to explore barriers around same-day ART initiation for infants receiving POC testing.

Indexed as

Early DiagnosisHIV InfectionsPoint-of-Care TestingAnti-HIV AgentsAnti-Retroviral AgentsFemaleHIV TestingHumansInfantInfant, NewbornInfectious Disease Transmission, VerticalMaleUgandaAnti-HIV AgentsAnti-Retroviral AgentsAntiretroviral therapyEarly infant diagnosisHIV-exposedPoint-of-careUganda

Identifiers

PMID38750529
PMCPMC11094911

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.